Page 2 - Yusri Elsayed News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Johnson & Johnson (JNJ) to Acquire Ambrx (AMAM) for $2 billion

Johnson & Johnson (JNJ) to Acquire Ambrx (AMAM) for $2 billion
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Yusri elsayedSenad karaahmetovicAmbrx biopharmaGlobal therapeutic area headJohnson innovative

J&J to acquire Ambrx Biopharma, a cancer drug developer, for $2B

The deal, which was announced on the first day of the annual JPMorgan Healthcare Conference, makes J&J the latest drugmaker to bet on ADCs.

Ambrx biopharmaYusri elsayedHealthcare conferenceBiotech and pharmaceuticalsHealth care industryAmbrx biopharma incJohnson ampBreaking newsPfizer incAbbvie incMerck amp co incBusiness news

Johnson & Johnson to Acquire Ambrx, Advancing Next Generation Antibody Drug Conjugates to Transform the Treatment of Cancer

Portfolio of Clinical and Preclinical Programs, Including Lead Product Candidate ARX517, a Prostate-Specific Membrane Antigen -Targeting Antibody Drug Conjugate , Strengthens Johnson & Johnson s.

Yusri elsayedMargaret yuJohnson the companyScripps research instituteAmbrx biopharma incExchange commissionAmbrx biopharmaGlobal therapeutic area headJohnson innovativeProstate cancer disease area leaderJohnson boardHart scott rodino antitrust improvements actInnovative medicineAnnual reportNote regarding forward lookingQuarterly report

Johnson & Johnson (JNJ) to Acquire Ambrx (AMAM) in $2B Deal

Johnson & Johnson (JNJ) to Acquire Ambrx (AMAM) in $2B Deal
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Margaret yuYusri elsayedAmbrx biopharma incScripps research instituteAmbrx biopharmaGlobal therapeutic area headJohnson innovativeProstate cancer disease area leader

Ambrx Biopharma soars on $2 billion takeover by Johnson & Johnson

Ambrx Biopharma is the latest cancer-drug specialist to be bought by a larger pharma over the past year.

Yusri elsayedAmbrx biopharmaDrug administrationBristol myers squibbFree reportCalifornia based ambrxNasdaq global selectPrometheus biosciencesMyers squibbMirati therapeuticsThe streetHe economyStock exchange